Neutropenia after the coadministration of clozapine and nirmatrelvir-ritonavir in a patient with SARS-CoV-2 infection: A case report with a literature review
BackgroundSchizophrenia is considered one of the major risk factors for mortality from SARS-CoV-2 infection. Early antiviral treatment is important to decrease the risk of mortality. Currently, Paxlovid (nirmatrelvir-ritonavir) has been widely used in SARS-CoV-2 patients with risk factors. However,...
Main Authors: | Chun-I Liu, Kah Kheng Goh, Chun-Hsin Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1096006/full |
Similar Items
-
The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia
by: Ebenezer Oloyede, et al.
Published: (2023-06-01) -
CLOZAPINE RECHALLENGE WITH LITHIUM AFTER DOUBLE INDUCED NEUTROPENIA: A CASE REPORT
by: A. Kourti, et al.
Published: (2019-01-01) -
Valproate-related neutropenia and lithium-related leukocytosis in patients treated with clozapine: a retrospective cohort study
by: Chia-Chun Yang, et al.
Published: (2023-03-01) -
Neutropenia in patients treated with clozapine during COVID-19 infection
by: J. Marti Bonany, et al.
Published: (2021-04-01) -
Clozapine‐associated severe eosinophilia following lithium rebound neutropenia: A case report
by: Kota Kikuchi, et al.
Published: (2020-12-01)